2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Kemurnian ≥98,0% Olaparib Intermediate Factory
Kemurnian Tinggi, Produksi Komersial
Olaparib lan intermediet sing gegandhengan:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formilbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)metil)asam benzoat CAS 763114-26-7
1-(Cyclopropylcarbonyl) piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Jeneng Kimia | 2-Fluoro-5-Formilbenzonitril |
| sinonim | 3-Cyano-4-Fluorobenzaldehida |
| Nomer CAS | 218301-22-5 |
| Nomer CAT | RF-PI451 |
| Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
| Formula Molekul | C8H4FNO |
| Bobot Molekul | 149.12 |
| Titik Lebur | 80,0 nganti 84,0 ℃ (lit.) |
| Kelarutan | Larut ing Metanol |
| Merk | Kimia Ruifu |
| Item | Spesifikasi |
| Penampilan | Bubuk kuning nganti putih |
| Kemurnian | ≥98,0% |
| Kelembapan (KF) | ≤0,50% |
| Total Impurities | ≤2,0% |
| Standar Tes | Standar Perusahaan |
| Panggunaan | Penengah Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
Paket: Botol, tas Aluminium foil, Drum Karton, 25kg / Drum, utawa miturut kabutuhan pelanggan.
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) digunakake kanggo nyiapake senyawa heterosiklik minangka inhibitor PARP kanggo panggunaan medis.2-Fluoro-5-Formylbenzonitrile digunakake minangka penengah saka Olaparib (CAS: 763113-22-0).Olaparib minangka inhibitor molekul cilik PARP1/PARP2 (IC50: 5/1 nM) nanging kurang efektif tumrap PARP tankyrase-1 (IC50: 1,5 µM).Olaparib (AZD-2281, jeneng dagang Lynparza) minangka terapi target sing disetujoni FDA kanggo kanker, dikembangake dening KuDOS Pharmaceuticals lan mengko dening AstraZeneca.Iki minangka inhibitor PARP, nyandhet poly ADP ribose polymerase (PARP), sawijining enzim sing melu ndandani DNA. Iki tumindak nglawan kanker ing wong sing mutasi BRCA1 utawa BRCA2 turun temurun, kalebu sawetara kanker ovarium, payudara, lan prostat.Ing Desember 2014, olaparib disetujoni kanggo digunakake minangka agen tunggal dening EMA lan FDA.Persetujuan FDA kanggo kanker ovarium majeng BRCA mutated (gBRCAm) germline sing wis nampa telung utawa luwih garis kemoterapi sadurunge.
